Vitreolytic ocriplasmin resolves vitreomacular traction

August 16, 2012
Vitreolytic ocriplasmin resolves vitreomacular traction
Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse events, according to a study published in the Aug. 16 in the New England Journal of Medicine.

(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse events, according to a study published in the Aug. 16 in the New England Journal of Medicine.

Peter Stalmans, M.D., Ph.D., from the Universitaire Ziekenhuizen Leuven in Belgium, and colleagues compared a single intravitreal injection of ocriplasmin with a placebo injection in two randomized clinical trials involving patients with symptomatic vitreomacular adhesion.

The researchers found that 464 eyes were treated with ocriplasmin and 188 with placebo. Vitreomacular adhesion was resolved in significantly more ocriplasmin-injected eyes than placebo-injected eyes (26.5 versus 10.1 percent). The prevalence of total posterior vitreous detachment was significantly increased in ocriplasmin- versus placebo-injected eyes (13.4 versus 3.7 percent). In 40.6 percent of ocriplasmin-treated eyes and 10.6 percent of placebo-treated eyes, nonsurgical closure of macular holes was achieved. A gain of at least three lines on the in best-corrected was more likely in ocriplasmin- versus placebo-treated eyes. Adverse events were seen in 68.4 and 53.5 percent of ocriplasmin-injected and placebo-injected eyes, respectively (P < 0.001), but the incidence of serious ocular adverse events was similar in the groups (P = 0.26).

"In conclusion, our study shows that enzymatic vitreolysis represents a means to resolve vitreomacular traction and to close macular holes," the authors write. "Intravitreal injection of ocriplasmin was superior to injection of placebo in altering the vitreoretinal interface of affected eyes, although it was accompanied by some, mainly transient, ocular ."

The study was funded by ThromboGenics, which manufactures ocriplasmin; several authors disclosed financial ties to pharmaceutical and biotechnology companies, including ThromboGenics.

Explore further: Vandetanib doesn't up survival in non-small-cell lung cancer

More information: Full Text (subscription or payment may be required)

Related Stories

Fluticasone improves histologic eosinophilia in esophagitis

June 29, 2012

(HealthDay) -- Swallowing aerosolized fluticasone improves histologic eosinophilia but does not improve dysphagia symptoms in adults with eosinophilic esophagitis (EoE), according to a study published online in the July issue ...

ECO: New weight loss drug effective in advanced obesity

May 14, 2012

(HealthDay) -- A new combination treatment of controlled-release phentermine/topiramate (PHEN/TPM CR) leads to significantly greater weight loss than a placebo even in individuals with significant obesity-related comorbidities, ...

Recommended for you

Binge drinking may quickly lead to liver damage

January 23, 2017

Alcohol consumed during just seven weeks of intermittent binge drinking harms the liver in ways that more moderate daily drinking does not, according to researchers at UC San Francisco.

$460-mn vaccine push to 'outsmart' viruses

January 19, 2017

With the world still reeling from outbreaks of deadly Ebola and baby-deforming Zika, governments and charities launched a $460-million (431 million-euro) initiative Thursday to "outsmart" infectious epidemics.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.